<DOC>
	<DOCNO>NCT01110629</DOCNO>
	<brief_summary>The objective study investigate efficacy safety lanthanum carbonate 750 2,250 mg Japanese Chronic Kidney Disease Stage 3 , 4 5 subject dialysis .</brief_summary>
	<brief_title>Study Chronic Kidney Disease ( CKD ) Not Dialysis</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Hyperphosphatemia</mesh_term>
	<criteria>Male female patient age 20 year time inform consent Chronic Kidney Disease patient Epidermal growth factor receptor ( eGFR ) 60 ml/min/1.73m2 ( stage 3 , 4 5 ) dialysis Patients care physician Chronic Kidney Disease &gt; 2 month expect begin dialysis least 4 month Patients serum phosphate level 5.6 mg/dL 11.0 mg/dL Week 4 ( Visit 1 ) Week 2 ( Visit 2 ) Patients hypocalcemia hypercalcemia ( correct serum calcium level &lt; 7.0 mg/dL &gt; / 11.0 mg/dL ) Week 2 ( Visit 2 ) . Significant renal impairment Had acute renal failure within 3 month Runin period</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Chronic kidney disease dialysis</keyword>
	<keyword>Lanthanum carbonate</keyword>
</DOC>